Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
Breast Cancer
About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring letrozole, metronomic, capecitabine, neoadjuvant, chemotherapy, ER+/HER2-
Eligibility Criteria
Inclusion Criteria:
-women (age 18-70 years) with clinical T2-3 N0-1 M0 ER-positive (ER) allred score 4-8,and progesterone receptor-positive (PgR) ,HER2-negative adequate bone marrow reserve (WBC count, 3.5 *109/L; platelets, 100*109/L; hemoglobin, 10g/dL), hepatic function (AST/ALT bilirubin and alkaline phosphatase levels 1.25 the upper limit of normal value), and renal function (serum creatinine 1.25 the upper limit of normal value).
Luminal A/ lymph node positive breast cancer or Luminal B breast cancer patients
Exclusion Criteria:
- (a) male patients; (b) patients with inflammatory breast cancer or distant metastasis; (c) patients who were previously treated with chemotherapy, radiation therapy or prior treatment with AIs or antiestrogens for breast cancer; (d) patients with a second concomitant neoplasm; and (e) patients who could not meet the eligibility criteria.
Sites / Locations
- Guangdong General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Letrozole Plus Low-Dose Metronomic Capecitabine
EC-T